These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26715578)

  • 21. A New Method for Model-Based Health Economic Evaluation Utilizing and Extending Moment-Generating Functions.
    Snowsill T
    Med Decis Making; 2019 Jul; 39(5):523-539. PubMed ID: 31319752
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
    Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
    HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
    Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
    Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discrete Event Simulation for Decision Modeling in Health Care: Lessons from Abdominal Aortic Aneurysm Screening.
    Glover MJ; Jones E; Masconi KL; Sweeting MJ; Thompson SG; ;
    Med Decis Making; 2018 May; 38(4):439-451. PubMed ID: 31665967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
    Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation.
    Hollingworth W; Spackman DE
    Acad Radiol; 2007 Apr; 14(4):406-10. PubMed ID: 17368208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
    J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accounting for costs, QALYs, and capacity constraints: using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services.
    Crane GJ; Kymes SM; Hiller JE; Casson R; Martin A; Karnon JD
    Med Decis Making; 2013 Nov; 33(8):986-97. PubMed ID: 23515216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.